Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.00 CAD | -102.27% |
| 2022 | 0.01 CAD | -7.04% |
| 2021 | 0.01 CAD | 123.91% |
| 2020 | -0.06 CAD | -19900.0% |
| 2019 | 0.00 CAD | 100.33% |
| 2018 | -0.09 CAD | -101.79% |
| 2017 | -0.04 CAD | -595.56% |
| 2016 | 0.01 CAD | 12.5% |
| 2015 | 0.01 CAD | 300.0% |
| 2014 | 0.00 CAD | 0.0% |
| 2013 | - CAD | 100.0% |
| 2012 | -0.04 CAD | 10.69% |
| 2011 | -0.05 CAD | 8.62% |
| 2010 | -0.05 CAD | 2.43% |
| 2009 | -0.05 CAD | 33.13% |
| 2008 | -0.08 CAD | -14.29% |
| 2007 | -0.07 CAD | -16.67% |
| 2006 | -0.06 CAD | -1766.67% |
| 2005 | 0.00 CAD | 1100.0% |
| 2004 | 0.00 CAD | 103.0% |
| 2003 | -0.01 CAD | -600.0% |
| 2002 | 0.00 CAD | -80.0% |
| 2001 | 0.01 CAD | 176.34% |
| 2000 | -0.01 CAD | 90.64% |
| 1999 | -0.14 CAD | -133.33% |
| 1998 | -0.06 CAD | -1835.48% |
| 1997 | -0.00 CAD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | 0.02 CAD | 23.29% |
| 2024 Q2 | 0.00 CAD | -84.44% |
| 2024 Q3 | 0.00 CAD | -35.71% |
| 2023 Q3 | -0.01 CAD | -366.67% |
| 2023 Q2 | -0.00 CAD | 88.89% |
| 2023 Q1 | -0.01 CAD | -163.41% |
| 2023 FY | - CAD | -102.27% |
| 2023 Q4 | 0.01 CAD | 360.71% |
| 2022 Q2 | 0.00 CAD | -47.14% |
| 2022 Q1 | 0.01 CAD | 2.94% |
| 2022 FY | - CAD | -7.04% |
| 2022 Q4 | -0.00 CAD | -228.13% |
| 2022 Q3 | 0.00 CAD | -13.51% |
| 2021 Q2 | 0.01 CAD | 600.0% |
| 2021 FY | - CAD | 123.91% |
| 2021 Q3 | 0.01 CAD | 85.71% |
| 2021 Q4 | 0.01 CAD | -47.69% |
| 2021 Q1 | 0.00 CAD | 102.11% |
| 2020 Q3 | -0.00 CAD | -81.82% |
| 2020 Q4 | -0.05 CAD | -1087.5% |
| 2020 FY | - CAD | -19900.0% |
| 2020 Q1 | -0.01 CAD | -1100.0% |
| 2020 Q2 | -0.00 CAD | 63.33% |
| 2019 Q1 | -0.00 CAD | 98.62% |
| 2019 Q2 | 0.00 CAD | 433.33% |
| 2019 FY | - CAD | 100.33% |
| 2019 Q4 | -0.00 CAD | 75.0% |
| 2019 Q3 | -0.00 CAD | -150.0% |
| 2018 Q3 | - CAD | 100.0% |
| 2018 Q2 | -0.00 CAD | -250.0% |
| 2018 Q1 | -0.00 CAD | 91.6% |
| 2018 Q4 | -0.09 CAD | 0.0% |
| 2018 FY | - CAD | -101.79% |
| 2017 FY | - CAD | -595.56% |
| 2017 Q1 | -0.04 CAD | -472.55% |
| 2017 Q4 | -0.01 CAD | -695.0% |
| 2017 Q3 | 0.00 CAD | -33.33% |
| 2017 Q2 | 0.00 CAD | 107.89% |
| 2016 Q4 | 0.01 CAD | 920.0% |
| 2016 FY | - CAD | 12.5% |
| 2016 Q1 | -0.00 CAD | -180.0% |
| 2016 Q2 | 0.00 CAD | 150.0% |
| 2016 Q3 | 0.00 CAD | -50.0% |
| 2015 Q2 | 0.00 CAD | 0.0% |
| 2015 Q1 | - CAD | 100.0% |
| 2015 Q4 | 0.01 CAD | 400.0% |
| 2015 Q3 | 0.00 CAD | -50.0% |
| 2015 FY | - CAD | 300.0% |
| 2014 Q3 | 0.00 CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2014 Q4 | -0.01 CAD | -270.0% |
| 2014 Q2 | 0.00 CAD | 50.0% |
| 2014 Q1 | 0.00 CAD | -78.95% |
| 2013 Q4 | 0.01 CAD | 733.33% |
| 2013 Q2 | 0.00 CAD | 134.91% |
| 2013 Q1 | -0.01 CAD | -19.1% |
| 2013 Q3 | -0.00 CAD | -140.54% |
| 2013 FY | - CAD | 100.0% |
| 2012 FY | - CAD | 10.69% |
| 2012 Q3 | -0.01 CAD | -40.59% |
| 2012 Q2 | -0.01 CAD | -13.48% |
| 2012 Q1 | -0.01 CAD | 3.26% |
| 2012 Q4 | -0.01 CAD | 37.32% |
| 2011 Q4 | -0.01 CAD | 31.85% |
| 2011 Q2 | -0.01 CAD | 16.55% |
| 2011 Q1 | -0.01 CAD | -2416.67% |
| 2011 Q3 | -0.01 CAD | -16.38% |
| 2011 FY | - CAD | 8.62% |
| 2010 Q2 | -0.01 CAD | 34.64% |
| 2010 Q4 | 0.00 CAD | 102.5% |
| 2010 FY | - CAD | 2.43% |
| 2010 Q1 | -0.02 CAD | 1.29% |
| 2010 Q3 | -0.02 CAD | -140.0% |
| 2009 Q3 | -0.01 CAD | -45.0% |
| 2009 Q2 | -0.01 CAD | 0.0% |
| 2009 Q1 | -0.01 CAD | -4.17% |
| 2009 FY | - CAD | 33.13% |
| 2009 Q4 | -0.02 CAD | -6.9% |
| 2008 Q3 | -0.02 CAD | 34.34% |
| 2008 Q4 | -0.01 CAD | 50.77% |
| 2008 Q2 | -0.03 CAD | -24.27% |
| 2008 Q1 | -0.02 CAD | -13.81% |
| 2008 FY | - CAD | -14.29% |
| 2007 Q4 | -0.02 CAD | 21.35% |
| 2007 Q3 | -0.03 CAD | -97.78% |
| 2007 Q2 | -0.01 CAD | 1.46% |
| 2007 Q1 | -0.01 CAD | 67.99% |
| 2007 FY | - CAD | -16.67% |
| 2006 Q4 | -0.04 CAD | -538.81% |
| 2006 Q3 | -0.01 CAD | 15.19% |
| 2006 Q2 | -0.01 CAD | -163.33% |
| 2006 FY | - CAD | -1766.67% |
| 2006 Q1 | -0.00 CAD | 11.76% |
| 2005 Q2 | 0.00 CAD | 216.67% |
| 2005 FY | - CAD | 1100.0% |
| 2005 Q1 | 0.00 CAD | -91.67% |
| 2005 Q4 | -0.00 CAD | -278.95% |
| 2005 Q3 | 0.00 CAD | -50.0% |
| 2004 FY | - CAD | 103.0% |
| 2004 Q2 | -0.00 CAD | 63.64% |
| 2004 Q3 | -0.01 CAD | -400.0% |
| 2004 Q4 | 0.01 CAD | 280.0% |
| 2004 Q1 | -0.00 CAD | -780.0% |
| 2003 Q3 | -0.00 CAD | -30.43% |
| 2003 Q2 | -0.00 CAD | 52.08% |
| 2003 Q1 | -0.00 CAD | -211.63% |
| 2003 FY | - CAD | -600.0% |
| 2003 Q4 | -0.00 CAD | 83.33% |
| 2002 Q2 | 0.00 CAD | 118.18% |
| 2002 Q4 | 0.00 CAD | 95.45% |
| 2002 Q3 | 0.00 CAD | 120.0% |
| 2002 FY | - CAD | -80.0% |
| 2002 Q1 | -0.01 CAD | -816.67% |
| 2001 Q4 | -0.00 CAD | -128.57% |
| 2001 Q3 | 0.00 CAD | -32.26% |
| 2001 Q2 | 0.00 CAD | 24.0% |
| 2001 Q1 | 0.00 CAD | 156.82% |
| 2001 FY | - CAD | 176.34% |
| 2000 FY | - CAD | 90.64% |
| 2000 Q4 | -0.00 CAD | 0.0% |
| 2000 Q3 | - CAD | 100.0% |
| 2000 Q2 | -0.01 CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 1999 Q2 | -0.02 CAD | -100.0% |
| 1999 Q3 | -0.01 CAD | 55.0% |
| 1999 Q1 | -0.01 CAD | -244.83% |
| 1999 Q4 | -0.10 CAD | -1011.11% |
| 1999 FY | - CAD | -133.33% |
| 1998 Q4 | -0.00 CAD | 71.0% |
| 1998 Q3 | -0.01 CAD | 66.67% |
| 1998 Q2 | -0.03 CAD | -50.0% |
| 1998 FY | - CAD | -1835.48% |
| 1998 Q1 | -0.02 CAD | -222.58% |
| 1997 Q1 | - CAD | 0.0% |
| 1997 Q4 | -0.01 CAD | -237.78% |
| 1997 Q3 | 0.00 CAD | 0.0% |
| 1997 Q2 | - CAD | 0.0% |
| 1997 FY | - CAD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Appili Therapeutics Inc. | -0.03 CAD | 99.038% |
| Eupraxia Pharmaceuticals Inc. | -1.58 CAD | 99.981% |
| Helix BioPharma Corp. | -0.21 CAD | 99.857% |
| Medicenna Therapeutics Corp. | -0.37 CAD | 99.919% |
| Satellos Bioscience Inc. | -0.18 CAD | 99.833% |
| Oncolytics Biotech Inc. | -0.41 CAD | 99.927% |
| Sernova Corp. | -0.13 CAD | 99.769% |